Cibus (CBUS) Debt Ratio (2016 - 2026)

Cibus (CBUS) posted Debt Ratio of 0.0 for Q4 2025, down 26.53% sequentially from 0.0 in Q3 2025, and down 8.47% YoY from 0.0 in Q4 2024.

Cibus (CBUS) Debt Ratio (2016 - 2026) Analysis & Trends

Cibus has reported Debt Ratio for 10 years, with the latest figure at 0.0 in Q4 2025.

Quarterly Debt Ratio fell 8.47% year-over-year to 0.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.0 (down 8.47% YoY) and the FY2025 annual result came in at 0.0, down 8.47% from the prior year.
Debt Ratio retreated to 0.0 in Q4 2025 per CBUS's latest filing, from 0.0 in the prior quarter.
Over five years, Debt Ratio peaked at 0.05 in Q1 2023 and troughed at 0.0 in Q2 2024.
A 5-year average of 0.01 and a median of 0.0 in 2023 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2023 and 2024: Debt Ratio jumped 2853.61% in 2023, then slumped 96.32% in 2024.
Over 5 years, Debt Ratio stood at 0.0 in 2021, then grew by 11.76% to 0.01 in 2022, then slumped by 51.34% to 0.0 in 2023, then slipped by 24.8% to 0.0 in 2024, then declined by 8.47% to 0.0 in 2025.
According to Business Quant data, Debt Ratio over the past three periods registered 0.0, 0.0, and 0.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	139.94 Bn	132.09 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.59 Bn	78.60 Bn	3.93 Bn	0.05
3	Argenx Se	65.67 Bn	60.49 Bn	1.37 Bn	-
4	Moderna	57.81 Bn	52.67 Bn	52.00 Mn	0.05
5	BeOne Medicines	42.25 Bn	37.15 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	31.76 Bn	28.45 Bn	992.69 Mn	-
7	BioNTech SE	28.41 Bn	10.02 Bn	668.28 Mn	0.03
8	Insmed	27.58 Bn	26.42 Bn	358.27 Mn	0.26
9	Royalty Pharma	27.24 Bn	26.41 Bn	-	0.47
10	Cibus	135.47 Mn	115.05 Mn	-	0.00

Download Data